Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts ...
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a specialized biopharmaceutical company headquartered in Cranford, New Jersey, focused on addressing serious unmet needs in critical care and oncology-adjacent indications through a relatively focused product portfolio. The company’s strategy emphasizes the development and commercialization of first-in-class (or novel) therapies that target difficult clinical ...Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a specialized biopharmaceutical company headquartered in Cranford, New Jersey, focused on addressing serious unmet needs in critical care and oncology-adjacent indications through a relatively focused product portfolio. The company’s strategy emphasizes the development and commercialization of first-in-class (or novel) therapies that target difficult clinical problems such as catheter-related bloodstream infections, tissue-expander related infections after breast reconstruction, painful inflammatory conditions like hemorrhoids, and life-threatening lung injury such as acute respiratory distress syndrome (ARDS).
From a product standpoint, Citius Pharmaceuticals’ pipeline highlighted in the provided description includes Mino-Lok, an antibiotic lock solution intended to combat catheter-related bloodstream infections by salvaging infected central venous catheters; Mino-Wrap, a liquifying gel-based wrap designed to reduce infections associated with tissue expanders used in breast reconstructive procedures; Halo-Lido, a topical formulation combining a corticosteroid with lidocaine for anti-inflammatory and numbing relief for hemorrhoids; and NoveCite, a mesenchymal stem cell therapy in development for ARDS. The company also lists I/ONTAK, an engineered fusion protein (IL-2 and diphtheria toxin) developed for persistent or recurrent cutaneous T-cell lymphoma. Collectively, these assets reflect a mix of anti-infective technologies, topical therapy, and advanced biologics/cell therapy.
Business-wise, Citius Pharmaceuticals aims to move products from development to market introduction and then expand commercial access. It also operates with a small organizational footprint (reported full-time employees around the low tens in the provided dataset), which is typical for development-stage biopharma firms that rely on clinical progress, partnerships, and disciplined operating structures. The company reports progress signals such as initial sales and revenue generation tied to product distribution networks (as referenced in the provided news bullet), consistent with a commercialization phase for at least part of its offering.
In terms of cost and financial context, the dataset provided shows profitability metrics that appear negative (e.g., negative returns on assets/equity and negative free cash flow measures on a trailing-twelve-month basis), which is common for biopharmaceutical companies during commercialization ramp-up and/or ongoing R&D investment. With relatively modest scale, fixed costs, R&D spend, and working-capital management can meaningfully impact quarterly results. Key people are centered around Leonard L. Mazur, who serves as CEO and is described as a co-founder and chairman, reflecting a leadership model often seen in specialized biotech firms.
Overall, Citius Pharmaceuticals’ “wish” or near-term success drivers are to demonstrate continued clinical and commercial traction across its limited but targeted pipeline, broaden real-world adoption of its critical care products, and strengthen financial performance as revenue generation becomes more meaningful relative to operating and development costs.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
-10.4%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-37.4M
+4.4%
+58.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
-110.0%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
+59.3%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
+53.4%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-26.6M
+5.8%
-567.5%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
-645.0%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
2.7%
+615.6%
+720.5%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
0.62x
+56.6%
+45.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
